Back to Results
First PageMeta Content
Business / Taxation / Financial statements / Income tax in the United States / Financial ratio / Balance sheet / Royalties / Tax / Net income / Accountancy / Finance / Generally Accepted Accounting Principles


News Release Astex Pharmaceuticals Reports 2013 Second Quarter Financial Results SGI-110 clinical data presented at EHA for Phase 1 MDS patients Second quarter royalty revenue increased 15% to $16.6 million Royalty reven
Add to Reading List

Open Document

File Size: 169,39 KB

Share Result on Facebook

City

DUBLIN / /

Company

MGI PHARMA / Janssen Pharmaceutica NV / Astex Pharmaceuticals Inc. / Eisai Corporation of North America / Conference Call Information Astex Pharmaceuticals / Astex Therapeutics Limited / Hospira Inc. / Mayne Pharma / Astex Pharmaceuticals Astex Pharmaceuticals / News Release Astex Pharmaceuticals / /

Country

United States / United Kingdom / /

Currency

USD / /

Event

Earnings Announcement / FDA Phase / M&A / Conference Call / /

IndustryTerm

telephone replay / pharmaceutical / /

MedicalCondition

refractory myelodysplastic syndrome / acute myeloid leukemia / /

Organization

Congress / World Congress / American Association of Cancer Research / American Society of Hematology / European Hematology Association / American Society of Clinical Oncology / /

Person

James S.J. Manuso / /

/

Position

General / chief executive officer and chairman / /

Product

Nipent / pentostatin / Dacogen / SGI-110 / Janssen Pharmaceutica NV / /

ProvinceOrState

California / /

PublishedMedium

Cancer Research / /

Technology

drug discovery / /

URL

http /

SocialTag